Key Considerations in Treatment Selection for Patients With Multiple Myeloma
Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed.
EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment
EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma
EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma
EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma
EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma
EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma
EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
EP: 11.Complying with REMS Training and Documentation Requirements
EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM
EP: 13.Unmet Needs in Multiple Myeloma Care
EP: 14.Treatment Sequencing and Combination Therapies for MM
EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM
This is a video synopsis/summary of a Practice Pearls involving Ryan Haumschild, PharmD, MS, MBA; Matthew Pianko, MD; and Anthony Perissinotti, PharmD, BCOP.
This video discusses considerations for selecting multiple myeloma patients for bispecific antibody treatment. Pianko explains that currently, bispecific antibodies are only available for patients who have had at least 4 prior therapy lines due to insurance coverage requirements. Main selection considerations are feasibility of managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome risks and ensuring sufficient resources to enable proper CRS mitigation protocols involving steroids and tocilizumab.
Pianko states step-up bispecific antibody dosing results in mostly mild CRS cases. He highlights bispecific antibodies’ more rapid, off-the-shelf initiation advantage. Regarding choosing among available bispecific antibodies, Pianko explains there are open questions about optimally sequencing the different immunotherapies in terms of distinct adverse effect profiles, potential impacts on subsequent chimeric antigen receptor (CAR) T-cell production, and lacking CAR T-cell maintenance therapy versus repeat bispecific antibody dosing potential. He states that while there are many sequencing factors to weigh, all the new options are currently viable choices, making this an exciting yet complex decision landscape needing more real-world evidence.
Video synopsis is AI-generated and reviewed by Pharmacy Times® editorial staff.
